Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better ...

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 ...

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical ...

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder ...

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell ...